MedMira Wins $4.2 million U.S. Army Contract to Commercialize Rapid Triple Test
June 30 2012 - 1:47PM
PR Newswire (Canada)
HALIFAX, July 3, 2012 /CNW/ - MedMira Inc., (MedMira) , a developer
of rapid diagnostic technology and solutions, announced today that
it has been awarded a U.S. Army Medical Research Acquisition
Activity (USAMRAA) contract to develop and commercialize a
rapid test capable of simultaneous detection of HIV and Hepatitis B
and C. The contract, awarded through a competitive bid process,
involves a two-year base period and a 10-month option with a value
of USD$4,266,144, if all options are exercised. MedMira
presented its technology and multiple rapid test, which met the
U.S. Army's advanced technology readiness level requirements.
The Multiplo Rapid HBV/HIV/HCV Antibody Test resulting from this
contract award will be deployed on the frontlines of military
healthcare for use in emergency screening for transfusion
transmitted diseases where no FDA approved donor screening tests
are available. The military could also put the test to use
during pre and post deployment screenings and civilian disaster
relief efforts. "We are thrilled to receive this new contract from
USAMRAA for the development and commercialization of our Multiplo
test. This contract award demonstrates the excellent fit
between MedMira's technology and products and military
requirements. We have built a lasting relationship with the
U.S. Army, delivering advanced diagnostic solutions that reduce the
need for militaries to undertake ground-up development work," said
Hermes Chan, CEO, MedMira Inc. "MedMira's technology and
products are elegantly simple, portable, fast, and high
quality. All of these attributes are mission critical in
deploying diagnostic healthcare solutions on the frontlines of
military healthcare." Chan continued, "Our team recently attended a
conference focused on military pre-hospital trauma management where
we heard first hand of the need for a multiple rapid HBV/HIV/HCV
test from many of the leading experts, military personnel, and
medical professionals in this field." Under contract number
W81XWH-12-C-0151 the U.S. Army will fund all development costs and
associated fees in obtaining a U.S. Food and Drug Administration
(FDA) premarket approval (PMA) for this multiple rapid test.
The scope of work under this contract will see MedMira advance and
fully commercialize a multiple rapid test that will simultaneously
detect three of the most serious infectious diseases, namely
HIV-1/2, Hepatitis B, and C antibodies within three minutes using
just a small drop of blood. Once approved, the product will be
supplied by MedMira directly to the U.S. Army and to other
customers throughout the world, both military and civilian, via the
Company's distribution network. "A multiplexed test for transfusion
transmitted diseases provides an enabling technology that will be
used to mitigate risk in austere environments where emergency blood
collections are necessary to save lives of severely wounded war
fighters," said Colonel Richard Gonzales, Product Manager, U.S.
Army Medical Materiel Development Activity. About MedMira MedMira
is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide
hospitals, labs, clinics and individuals with reliable, rapid
diagnosis for diseases such as HIV and hepatitis C in just three
minutes. The company's tests are sold under the Reveal®, Multiplo™
and Miriad brands in global markets. MedMira's rapid flow-through
HIV test is the only one in the world to achieve regulatory
approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada. For more information visit
MedMira's website at www.medmira.com. This news release contains
forward-looking statements, including statements relating to growth
in the Company's business, earnings and profitability, and trends
in demand for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. SOURCE
MEDMIRA INC. Image with caption: "Under a US Army contract valued
at USD$4.2 million, MedMira will develop and commercialize this
multiple rapid test which detects HIV, Hepatitis B and C
simultaneously in 3 minutes from a single drop of blood. (CNW
Group/MEDMIRA INC.)". Image available at:
http://photos.newswire.ca/images/download/20120703_C5808_PHOTO_EN_15891.jpg
MEDMIRA INC. CONTACT: MedMira Contact:Andrea Young, Corporate
CommunicationsTel: 902-450-1588Email: ayoung@medmira.com
Copyright
MedMira (TSXV:MIR)
Historical Stock Chart
From Sep 2024 to Oct 2024
MedMira (TSXV:MIR)
Historical Stock Chart
From Oct 2023 to Oct 2024